Market Closed - Nyse 04:00:02 2024-03-27 pm EDT 5-day change 1st Jan Change
21.63 USD +5.36% Intraday chart for Artivion, Inc. +4.44% +20.97%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Artivion Files Mixed Shelf MT
Artivion Insider Sold Shares Worth $1,358,818, According to a Recent SEC Filing MT
Stifel Raises Price Target on Artivion to $22 From $20, Maintains Buy Rating MT
Earnings Flash (AORT) ARTIVION Reports Q4 EPS $0.11 MT
Earnings Flash (AORT) ARTIVION Reports Q4 Revenue $93.7M, vs. Street Est of $89.3M MT
Transcript : Artivion, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Artivion, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Artivion, Inc. Provides Earnings Guidance for the Year 2024 CI
Artivion Enters $350 Million Credit Facilities MT
Artivion, Inc. Obtains $350 Million in Senior Secured Credit Facilities CI
Artivion, Inc. announced that it expects to receive $350 million in funding CI
Artivion Insider Sold Shares Worth $273,543, According to a Recent SEC Filing MT
Artivion, Inc. Announces Chief Financial Officer Changes CI
Artivion Completes Enrollment in Clinical Trial of Aortic Arch Remodeling Device MT
Artivion, Inc. Announces Completion of Enrollment in PERSEVERE Trial CI
Earnings Flash (AORT) ARTIVION Reports Q3 EPS $0.02, vs. Street Est of $0.03 MT
Earnings Flash (AORT) ARTIVION Posts Q3 Revenue $87.9M, vs. Street Est of $84.3M MT
Transcript : Artivion, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Artivion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Artivion, Inc. Revises Earnings Guidance for the Year 2023 CI
Artivion, Inc. Announces Data from On-X Aortic Heart Valve Low INR Post-Market Study Presented in A Late-Breaking Science Session At the 37European Association for Cardio-Thoracic Surgery Annual Meeting CI
Transcript : Artivion, Inc. Presents at 31st Annual Deutsche Bank Leveraged Finance Conference, Oct-03-2023 01:40 PM
Transcript : Artivion, Inc., Q2 2023 Earnings Call, Aug 03, 2023
Earnings Flash (AORT) ARTIVION Posts Q2 EPS $0.06, vs. Street Est of $0.02 MT
Earnings Flash (AORT) ARTIVION Posts Q2 Revenue $89.3M, vs. Street Est of $84.2M MT
Chart Artivion, Inc.
More charts
Artivion, Inc. is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease, heart valve disease, aortic aneurysms, and dissections. Its segments include in two segments: Medical Devices and Preservation Services. The Medical Devices segment includes sales of aortic stent grafts, surgical sealants, and On-X. The Preservation Services segment includes services for the preservation of cardiac and vascular implantable human tissues. It has four product families: aortic stent grafts, surgical sealants, On-X mechanical heart valves and related surgical products, and implantable cardiac and vascular human tissues. Aortic stent grafts include aortic arch stent grafts, abdominal stent grafts, and synthetic vascular grafts. Surgical sealants include BioGlue Surgical Adhesive (BioGlue) products. It also sells or distributes PhotoFix bovine surgical patches.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
21.63 USD
Average target price
25.15 USD
Spread / Average Target
+16.27%
Consensus
  1. Stock
  2. Equities
  3. Stock Artivion, Inc. - Nyse
  4. News Artivion, Inc.
  5. CryoLife : Needham Adjusts CryoLife's Price Target to $39 From $38, Maintains Buy Rating